Dec
2018
The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Facebook
Twitter
Google+
LinkedIn
Pinterest
Stumbleupon
